| Active ingredient (INN) | Adalimumab |
|---|---|
| Brand names | Humira, Hadlima, Hyrimoz, Yusimry, Abrilada, Amjevita +3 more |
| ATC level 5 | L04AB04 |
| ATC level 4 | L04AB |
| Drug class | Anti-TNF-alpha monoclonal antibody |
| Therapeutic category | Immunology/Rheumatology |
| Strength | 40mg/0.8ml · 80mg/0.8ml · 20mg/0.2ml paediatric |
| Dosage form | solution for injection |
| Route of administration | subcutaneous |
| Controlled substance | No |
| Marketing-authorisation holders | Pfizer Australia Pty Ltd, Cipla Australia Pty Ltd, Samsung Bioepis AU Pty Ltd, Sandoz Pty Ltd +1 more |
| Registrations on file | 16 |
| Patient information leaflet (PIL) | Not on file |
| Summary of product characteristics (SPC) | Not on file |
| Product | Strength | Form | Market | MA holder | Status |
|---|---|---|---|---|---|
| ABRILADA adalimumab | 40 mg | — | 🇦🇺 AU | Pfizer Australia Pty Ltd | Active |
| HULIO adalimumab | 40 mg | — | 🇦🇺 AU | — | Active |
| HULIO adalimumab | 20 mg | — | 🇦🇺 AU | — | Active |
| ABRILADA adalimumab | 20 mg | — | 🇦🇺 AU | Pfizer Australia Pty Ltd | Active |
| YUFLYMA adalimumab | 40 mg | — | 🇦🇺 AU | — | Active |
| CIPTUNEC adalimumab | 40 mg | — | 🇦🇺 AU | Cipla Australia Pty Ltd | Active |
| CIPTUNEC adalimumab | 80 mg | — | 🇦🇺 AU | Cipla Australia Pty Ltd | Active |
| ADALICIP adalimumab | 40 mg | — | 🇦🇺 AU | Cipla Australia Pty Ltd | Active |
| YUFLYMA adalimumab | 80 mg | — | 🇦🇺 AU | — | Active |
| HADLIMA adalimumab | 40 mg | — | 🇦🇺 AU | Samsung Bioepis AU Pty Ltd | Active |
| ADALICIP adalimumab | 80 mg | — | 🇦🇺 AU | Cipla Australia Pty Ltd | Active |
| HYRIMOZ adalimumab | 40 mg | — | 🇦🇺 AU | Sandoz Pty Ltd | Active |
| HYRIMOZ adalimumab | 80 mg | — | 🇦🇺 AU | Sandoz Pty Ltd | Active |
| HYRIMOZ adalimumab | 20 mg | — | 🇦🇺 AU | Sandoz Pty Ltd | Active |
| HUMIRA adalimumab | 20 mg | — | 🇦🇺 AU | Abbvie Pty Ltd | Active |